Evidence map›Paper›PMID 37871202›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Developing synthetic tools to decipher the tumor-immune interactome.

Orr-El Weizman, Sophia Luyten, Peiwen Lu, Eric Song, Kai Qin, Darius Mostaghimi, Aaron M Ring, Akiko Iwasaki

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Orr-El WeizmanDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
Sophia LuytenDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
Peiwen LuDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
Eric SongDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
Kai QinDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
Darius MostaghimiDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
Aaron M RingDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0003-3699-2446
Akiko IwasakiDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.ORCID 0000-0002-7824-9856

Funding

Immunity to Genital Herpes Simplex-2R01AI054359 · NIAID · YALE UNIVERSITY · PI IWASAKI, AKIKO · 2004 to 2019
$5.2M
Viral and immune-mediated CNS pathology during SARS-CoV-2 infectionR01AI157488 · NIAID · YALE UNIVERSITY · PI FARHADIAN, SHELLI, IWASAKI, AKIKO · 2020 to 2024
$4.7M
Predoctoral Training Program in VirologyT32AI055403 · NIAID · YALE UNIVERSITY · PI KUMAR, PRITI, MOTHES, WALTHER H · 2003 to 2024
$3.6M
Role of viral infections in potassium channel-related cerebellar ataxiaR01NS111242 · NINDS · YALE UNIVERSITY · PI IWASAKI, AKIKO, KACZMAREK, LEONARD K · 2019 to 2023
$2.7M
B cell based protection against recurrent herpesR01AI127429 · NIAID · YALE UNIVERSITY · PI IWASAKI, AKIKO · 2017 to 2021
$2.1M
Investigating the tumor-immune interactome in metastasesF99CA264425 · NCI · YALE UNIVERSITY · PI WEIZMAN, ORR-EL · 2021 to 2022
$94k
NCI NIH HHS F99 CA264425NIAID NIH HHS R01 AI054359NIAID NIH HHS R01 AI127429NIAID NIH HHS R01 AI157488NIAID NIH HHS T32 AI055403NINDS NIH HHS R01 NS111242
6 · The paper itself

Abstract

The ability of immune cells to directly interact with transformed cells is an essential component of immune surveillance and critical for optimal tissue function. The tumor-immune interactome (the collective cellular interactions between oncogenic cells and immune cells) is distinct and varied based on the tissue location and immunogenicity of tumor subtypes. However, comprehensive landscape and the consequences of tumor-interacting immune cells in the tumor microenvironment are not well understood. Current tools are limited in their ability to identify and record interactors in vivo or be utilized for downstream analysis. Here, we describe the development and validation of a technology leveraging synthetic Notch receptors reporting physical tumor cell-immune cell contact in vivo in order to decipher the tumor-immune interactome. We call this approach, Tumor-Immune Interactome Non-biased Discovery Retroviral Reporter or TIINDRR. Using TIINDRR, we identify the tumor-immune interactomes that define immunological refractory and sensitive tumors and how different immunotherapies alter these interactions. Thus, TIINDRR provides a flexible and versatile tool for studying in-vivo tumor-immune cell interactions, aiding in the identification of biologically relevant information needed for the rational design of immune-based therapies.

Indexed as

NeoplasmsCell CommunicationHumansHydrolasesImmunologic SurveillanceImmunotherapyTumor MicroenvironmentHydrolasescancer immunologyimmunotherapymyeloid cellssurveillanceT cells

Identifiers

PMID37871202
PMCPMC10622925

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.